Sandoz Expands Rivaroxaban Access in Germany

Sandoz Group AG announces the launch of generic rivaroxaban in Germany, offering strengths of 10 mg, 15 mg, and 20 mg. The new product, Rivaroxaban - 1 A Pharma®, provides a cost-effective alternative to Bayer's Xarelto® with a price advantage across all strengths.

This move follows Sandoz's successful challenge of a dosage patent in Germany, marking an important step in enhancing access to affordable anticoagulant therapies. The company plans to broaden its market reach by introducing rivaroxaban in additional countries soon.

Previously, Sandoz introduced the 2.5 mg strength in 2024, after the primary patent expired. Now, by entering all open-house discount agreements for rivaroxaban in Germany, Sandoz is further pushing for affordability and accessibility in this essential therapeutic area.